These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 24080653)

  • 1. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.
    Robbie GJ; Criste R; Dall'acqua WF; Jensen K; Patel NK; Losonsky GA; Griffin MP
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6147-53. PubMed ID: 24080653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
    Fernández P; Trenholme A; Abarca K; Griffin MP; Hultquist M; Harris B; Losonsky GA;
    BMC Pediatr; 2010 Jun; 10():38. PubMed ID: 20525274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults.
    Yu XQ; Robbie GJ; Wu Y; Esser MT; Jensen K; Schwartz HI; Bellamy T; Hernandez-Illas M; Jafri HS
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).
    Dall'Acqua WF; Kiener PA; Wu H
    J Biol Chem; 2006 Aug; 281(33):23514-24. PubMed ID: 16793771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An "Fc-Silenced" IgG1 Format With Extended Half-Life Designed for Improved Stability.
    Borrok MJ; Mody N; Lu X; Kuhn ML; Wu H; Dall'Acqua WF; Tsui P
    J Pharm Sci; 2017 Apr; 106(4):1008-1017. PubMed ID: 28057542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
    O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
    Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural characterization of a human Fc fragment engineered for extended serum half-life.
    Oganesyan V; Damschroder MM; Woods RM; Cook KE; Wu H; Dall'acqua WF
    Mol Immunol; 2009 May; 46(8-9):1750-5. PubMed ID: 19250681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.
    Ramilo O; Lagos R; Sáez-Llorens X; Suzich J; Wang CK; Jensen KM; Harris BS; Losonsky GA; Griffin MP;
    Pediatr Infect Dis J; 2014 Jul; 33(7):703-9. PubMed ID: 24356256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques.
    Rosenberg YJ; Lewis GK; Montefiori DC; LaBranche CC; Lewis MG; Urban LA; Lees JP; Mao L; Jiang X
    PLoS One; 2019; 14(2):e0212649. PubMed ID: 30785963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies.
    Dippel A; Gallegos A; Aleti V; Barnes A; Chen X; Christian E; Delmar J; Du Q; Esfandiary R; Farmer E; Garcia A; Li Q; Lin J; Liu W; Machiesky L; Mody N; Parupudi A; Prophet M; Rickert K; Rosenthal K; Ren S; Shandilya H; Varkey R; Wons K; Wu Y; Loo YM; Esser MT; Kallewaard NL; Rajan S; Damschroder M; Xu W; Kaplan G
    MAbs; 2023; 15(1):2152526. PubMed ID: 36476037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.
    Abarca K; Jung E; Fernández P; Zhao L; Harris B; Connor EM; Losonsky GA;
    Pediatr Infect Dis J; 2009 Apr; 28(4):267-72. PubMed ID: 19258920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.
    Lagos R; DeVincenzo JP; Muñoz A; Hultquist M; Suzich J; Connor EM; Losonsky GA
    Pediatr Infect Dis J; 2009 Sep; 28(9):835-7. PubMed ID: 19636278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
    Zhu Q; McLellan JS; Kallewaard NL; Ulbrandt ND; Palaszynski S; Zhang J; Moldt B; Khan A; Svabek C; McAuliffe JM; Wrapp D; Patel NK; Cook KE; Richter BWM; Ryan PC; Yuan AQ; Suzich JA
    Sci Transl Med; 2017 May; 9(388):. PubMed ID: 28469033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA
    J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.
    Weisman LE
    Curr Opin Mol Ther; 2009 Apr; 11(2):208-18. PubMed ID: 19330726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model.
    Mejías A; Chávez-Bueno S; Raynor MB; Connolly J; Kiener PA; Jafri HS; Ramilo O
    Virol J; 2007 Oct; 4():109. PubMed ID: 17961258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-Pore Minimum Physiologically-based Pharmacokinetic Model to Describe the Disposition of Therapeutic Monoclonal IgG Antibody in Humans.
    Hardiansyah D; Ng CM
    Pharm Res; 2018 Feb; 35(3):47. PubMed ID: 29411151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
    Gaudinski MR; Coates EE; Houser KV; Chen GL; Yamshchikov G; Saunders JG; Holman LA; Gordon I; Plummer S; Hendel CS; Conan-Cibotti M; Lorenzo MG; Sitar S; Carlton K; Laurencot C; Bailer RT; Narpala S; McDermott AB; Namboodiri AM; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
    PLoS Med; 2018 Jan; 15(1):e1002493. PubMed ID: 29364886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection.
    Deng R; She G; Maia M; Lim JJ; Peck MC; McBride JM; Kulkarni P; Horn P; Castro A; Newton E; Tavel JA; Hanley WD
    J Clin Pharmacol; 2020 Nov; 60(11):1509-1518. PubMed ID: 32621543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation and characterization of QLS22001, a humanized monoclonal antibody that neutralizes IL-17A and IL-17F with an extended half-life.
    Ma H; Zhang W; Liu K; Xu B; Li M; Meng Q; An Z; Chen B
    Int Immunopharmacol; 2023 Apr; 117():109947. PubMed ID: 37012892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.